Clin Mol Hepatol.  2019 Mar;25(1):21-29. 10.3350/cmh.2018.1007.

Radiomics and radiogenomics of primary liver cancers

• Jeong WK
• Jamshidi N
• Felker ER
• Raman SS
• Lu DS

• KMID: 2447246
• DOI: http://doi.org/10.3350/cmh.2018.1007

Abstract

Concurrent advancements in imaging and genomic biomarkers have created opportunities to identify non-invasive imaging surrogates of molecular phenotypes. In order to develop such imaging surrogates radiomics and radiogenomics/imaging genomics will be necessary; there has been consistent progress in these fields for primary liver cancers. In this article we evaluate the current status of the field specifically with regards to hepatocellular carcinoma and intrahepatic cholangiocarcinoma, highlighting some of the up and coming results that were presented at the annual Radiological Society of North America Conference in 2017. There are an increasing number of studies in this area with a bias towards quantitative feature measurement, which is expected to benefit reproducibility of the findings and portends well for the future development of biomarkers for diagnosis, prognosis, and treatment response assessment. We review some of the advancements and look forward to some of the exciting future applications that are anticipated as the field develops.

Keyword

Hepatocellular carcinoma; Cholangiocarcinoma; Tumor biomarker; Computed tomography; Genomics

MeSH Terms

Bias (Epidemiology)
Biomarkers
Carcinoma, Hepatocellular
Cholangiocarcinoma
Diagnosis
Genomics
Liver Neoplasms*
Liver*
North America
Phenotype
Prognosis
Biomarkers